		•					Sheet1	_ or _2_
FORM PTO-	U.S. DEPARTM PATENT AND T	ENT OF COM	MERCE OFFICE	ATTY. DOCK A061CIP2	ET NO.		RIAL NO. 086,217	
	INFORMATION DISCL STATEMENT BY APP	OSURE	Nakorici O.	APPLICANT Gregory R. Mr Toshiyuki Yon	undy and neda	511	NFIRMAT	
		/ %	ITENT & TRIBE	FILING DATE February 21,		GR(	OUP <sup>4</sup> j(	ECEIVE
			ENT DOCUM	ENTS			TECHO	
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLAS	s	FILING IF APPROF	DATE 1600/2
WH	5,510,332	4/23/96	Kogan et al	. 514	14		July 7, 19	
		FOREIGN PA	ATENT DOCL	JMENTS	·			
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLAS	ss	TRANSI YES	ATION NO
m+	WO 99/61421	12/2/99	PCT	-C07D	207/10 >	寸		
mu	WO 00/15247	3/23/00	PCT	ABIK	38/17	T		
wat	WO 01/12186	2/22/01	PCT	A <del>61K</del>	31/40	$\Box$		
						_		
					ļ	4		
				<del></del>	<b>}</b>	-+		
	ļ			<del> </del>	<del></del>	+		
				<del> </del>	<del> </del>	+		
				<del> </del>	<del> </del>	+		
				<del> </del>	<del> </del>	+		
				<del> </del>	<del> </del>	+		
				1	<del>                                     </del>	_		
,				1		7		
						$\Box$		
						$\perp$		
						$\perp$		
				<u> </u>		4		
				ļ		4		
				1		_		

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.

**EXAMINER** 

U.S. DEPARTMENT OF COMMERCE ATTY, DOCKET NO. SERIAL NO. FORM PTO-1449 10/086,217 A061CIP2 PATENT AND TRADEMARI APPLICANT CONFIRMATION NO. INFORMATION DISCLOSURE Gregory R. Mundy and 5114 STATEMENT BY APPLICANTO Toshiyuki Yoneda RECEIVED GROUP FILING DATE February 21, 2002 1644 OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) FXAMINER INITIAL Masellis-Smith et al. "Adhesion of Multiple Myeloma Peripheral B Cells to Bone Marrow Fibroblasts: A mu Requirement for CD44 and α<sub>4</sub>β<sub>7</sub>", Cancer Research 57(5): 930-936 (1997). Roodman GD "Mechanisms of Bone Lesions in Multiple Myeloma and Lymphoma". Database Medline mH 'Online!: US National Library of Medicine (NLM), Bethesda, MD, US, retrieved from STN, Database accession no. 1998026745 abstract. Roodman GD "Mechanisms of Bone Lesions in Multiple Myeloma and Lymphoma", Cancer 80 (8 my Suppl): 1557-1563 (1997, Oct. 15). Akatsu et al. "Chinese Hamster Ovary Cells Expressing Alpha4beta1 Integrin Stimulate Osteoclast mst Formation In Vitro", Database BIOSIS 'Online!: Biosciences Information Service, Philadelphia, PA, US, (August 1998) Database accession no. PREV199800429141, abstract. Akatsu et al. "Chinese Hamster Ovary Cells Expressing α<sub>a</sub>β, Integrin Stimulate Osteoclast Formation In my Vitro", Journal of Bone and Mineral Research 13 (8): 1251-1259 (1998). Michigami et al. "Interactions of Myeloma Cells with Bone Marrow Stromal Cells via Alpha4 Beta1 mx Integrin - VCAM-1 is required for the Development of Osteolysis". Database SCISEARCH 'Online! retrieved from STN, Database accession no. 684996. Michigami et al. "Interactions of Myeloma Cells with Bone Marrow Stromat Cells via a A Integrio - VCAMy is required for the Development of Osteolysis", Journal of Bone and Mineral Research 12 Supp. 1, p.S 128, Abstract 104 (1997). Mori et al. "Anti-a4 Integrin Antibody Suppresses the Bone Disease of Myeloma and Disrupts MH Myeloma-marrow Stromal Cell Interactions", Journal of Bone and Mineral Research 14 Supp. 1, p. S173, Abstract 1161 (1999).

EXAMINER Maher Haddad

DATE CONSIDERED

40/22/04

OCT 2 0 2003 2

Substitute Form PTO-1449 U.S. Department of Patent and Trade (Mognified) Information Disclosur Statement

(37 CFR §1.98(b))

U.S. Department of Commerce Patent and Trademark Office Attorney's Docket No. 10274-063001

Attorney's Docket No. 10274-063001
Applicant

Application No. 10/086,217

by Applicant (Use several sheets if necessary)

Mundy et al.
Filing Date
February 21, 2002

Group Art Unit 1644

			U.S. Patent	Documents			
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA						
	AB					4	
	AC						
	AD						
	AE			0			

	Foreig	n Patent Doo	uments or Pu	blished Foreign	Patent A	Application	าร	
Examiner	Desig.	Document	Publication	Country or			Trans	slation
Initial	ID	Number	Date	Patent Office	Class	Subclass	Yes	No
	AF							
	AG							
	AH							

	Other D	ocuments (include Author, Title, Date, and Place of Publication)
Examiner	Desig.	
Initial	Ð	Document
МH	AI	Damiano et al., "Integrin-Mediated Drug Resistance in Multiple Myeloma", 2000, Leukemia and Lymphama, vol. 38 (1-2):71-81
MH	AJ	Damiano et al., "Cell Adhesion Mediated Drug Resistance (CAM-DR): Role of Integrins", March 1, 1999, Blood, vol. 93(5):1658-1667
m#	AK	Mundry et al., "Stromal cells regulate survival of B-lineage leukernic cells", Sept. 1, 2000, Blood, vol. 96 (5):1926-1932

Examiner Signature

Maker Haddad

Date Considered

10/27/04

ATTY, DOCKET NO. SERIAL NO. U.S. DEPARTMENT OF COMMERCE FORM PTO-1449 PATENT AND TRADEMARK 10/086,217 A061CIP2 APPLICANT CONFIRMATION NO. INFORMATION DISCLOSURE Gregory R. Mundy and 5114 STATEMENT BY APPLICAN Toshiyuki Yoneda FILING DATE GROUP February 21, 2002 1644

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
m#	US 2002/0022028 A1	2/21/2002	Mundy et al.	424	142.1	March 13, 2001
mH	US 2002/0041874 A1	4/11/2002	Mundy et al.	424	131.1	August 31, 2001

EXAMINER Wahen Hoobland

DATE CONSIDERED

10/27/04

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. A061CIP2	SERIAL NO. 10/086,217
	DEMATION DISCLOSURE TEMENT BY APPLICANT JUN 2 1 2002	APPLICANT Gregory R. Mundy and Toshiyuki Yoneda	CONFIRMATION NO. 5114
	STENCE TRADENSE	FILING DATE February 21, 2002	GROUP 1644

	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
EXAMINER INITIAL	
mas	Alsina, M. et al., "Development of an In Vivo Model of Human Multiple Myeloma Bone Disease," <u>BLOOD</u> 87: 1495-1501 (1996).
mar	Attal, M. et al., "A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma," N ENGL J MED 335: 91-97 (1996).
ma	Atkins, C., "Correspondence: High-Dose Chemotherapy in Multiple Myeloma," N.ENGL J MED 335: 1844 (1995).
mu	Oivanen, T. M. et al., "Correspondence: High-Dose Chemotherapy in Multiple Myeloma," N ENG J MED 335: 1844-1845 (1996).
may	Attal, M. et al., "Correspondence: High-Dose Chemotherapy in Multiple Myeloma - In Reply," N ENGL J MED 335: 1844-1845 (1996).
me	Barlogie, B. et al., "Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients," <u>BLOOP</u> 98: 492-494 (2001).
my	Bataille, R. et al., "Serum Levels of Interleukin 6, a Potent Myeloma Cell Growth Factor, as a Reflect of Disease Severity in Plasma Cell Dyscrasias," J CLIN INVEST 84: 2008-2011 (1989).
mu	Bataille, R. et al., "Mechanisms of Bone Lesions In Multiple Myeloma," <u>HEMATOLOGY/ONCOLOGY</u> CLINICS OF NORTH AMERICA 6: 285-295 (1992).
me	Bataille, R. et al., "Biologic Effects of Anti-Interleukin-6 Murine Monoclonal Antibody in Advanced Multiple Myeloma," BLOOD 86: 685-691 (1995).
hall-	Berenson, J. R. et al., "Long-Term Pamidronate Treatment of Advanced Multiple Myeloma Patients Reduces Skeletal Events," JCLIN ONCOL 16: 593-602 (1998).
ma.	Seymour, J. F., "Correspondence: Long-Term Pamidronate in Multiple Myeloma," <u>J CLIN ONCOL</u> 16: 2572 (1998).
mts	Berenson, J. R., "Correspondence: Long-Term Pamidronate in Multiple Myeloma - In Reply," J. CLIN ONCOL 16: 2572-2573 (1998).
hutt	Boyce, B. F. et al., "Bolus Injections of Recombinant Human Interleukin-1 Cause Transient Hypocalcemia in Normal Mice," <u>ENDOCRINOLOGY</u> 125: 2780-2783 (1989).
₩#	Chauhan, D. et al., "Regulation of Interleukin 6 in Multiple Myeloma and Bone Marrow Stromal Cells," STEM CELLS 13 (suppl 2): 35-39 (1995).
<b>~</b> #	Dallas, S. L. et al., "Ibandronate Reduces Osteolytic Lesions but not Tumor Burden in a Murine Model of Myeloma Bone Disease," BLOOD 93: 1697-1706 (1999).

EVANINED			DATE CONCIDENCE
EXAMINER	Maker	the ded and	DATE CONSIDERED 10/27/04

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. A061CIP2	SERIAL NO. 10/086,217
INF ST	ORMATION DISCLOSURE OF E	APPLICANT Gregory R. Mundy and Toshiyuki Yoneda	CONFIRMATION NO. 5114
	JUN 2 1 2002 \$\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\	FILING DATE February 21, 2002	GROUP 1644
	TRADEMIN		

	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
EXAMINER INITIAL	
MH	Epstein, J., "Myeloma Phenotype: Clues To Disease Origin and Manifestation," HEMATOLOGY/ONCOLOGY CLINICS OF NORTH AMERICA 6:249-256 (1992).
MH	Garrett, I. R. et al., "A Murine Model of Human Myeloma Bone Disease," BONE 20: 515-520 (1997).
mH	Gosslar, U. et al., "Predominant Role of α4-integrins for distinct steps of lymphoma metastasis," Proc. Natl. Acad. Sci. USA 93: 4821-4826 (1996).
m H	MacDonald, B. R. et al., "Effects of Human Recombinant CSF-GM and Highly Purified CSF-1 on the Formation of Multinucleated Cells with Osteoclast Characteristics in Long-Term Bone Marrow Cultures," J BONE AND MINERAL RESEARCH 1: 227-233 (1980).
MH	Matsuura, N. et al., "Induction of Experimental Bone Metastasis in Mice by Transfection of Integrin α4β1 into Tumor Cells," AM J PATHOL 148: 55-61 (1996).
MH	Michigami, T. et al., "Interactions of Myeloma Cells with Bone Marrow Stromal Cells Via α4β1 Integrin- VCAM-1 is Required For the Development of Osteolysis," <u>Mineteenth Annual Meeting of the American</u> Society for Bone and Mineral Research, Cincinnati, Chip: Abstract 104 (9/14/1997); <u>J. BONE AND</u> MINERAL RESEARCH 12 Supplement: p. S216 (1997).
MH	Michigami, T. et al., "Cell-cell contact between marrow stromal cells and myeloma cells via VCAM-1 and α4β1-integrin enhances production of osteoclast-stimulating activity," <u>BLOOD</u> 96: 1953-1960 (2000).
мH	Mittelman, M. et al., "Erythropoietin induces tumor regression and antitumor immune responses in murine myeloma models," Proc. Natl. Acad. Sci. USA 98: 5181-5186 (2001).
mH	Mori, Y. et al., "Anti-α4 Integrin Antibody Suppresses the Bone Disease of Myetoma and Disrupts Myetoma-Marrow Stromal Cell Interactions," Twenty-First Annual Meeting of the American Society for Bone and Mineral Research, St. Louis, Missouri, Abstract 1161 (10/3/1998); J. BONE AND MINERAL RESERACH 14 Supplement 1: p. S148 (1999).
MH	Mundy, G. R. and Bertolini, D. R., "Bone Destruction and Hypercalcemia in Plasma Cell Myeloma," SEMINARS IN ONCOLOGY 13: 291-299 (1986).
mH	Mundy, G. R., "Myeloma Bone Disease," EURO J CANCER 34: 246-251 (1998).
мH	Oyajobi, B. O. et al., "Expression of Rank Ligand (RankL) By Myeloma Cells Requires Binding To Bone Marrow Stromal Cells Via An α4β1-VCAM-1 Interaction," Second Joint Meeting of The American Society for Bone and Mineral Research and The International Bone and Mineral Society, San Francisco, California: Abstract 1133 (12/4/1998); BONE 23(5 Supplement): p. S180 (1998).
мH	Papayannopoulou, T. and Nakamoto, B., "Peripheralization of hemopoletic progenitors in primates treated with anti-VLA, integrin," Proc. Natl. Acad. Sci. USA 90: 9374-9378 (1993).
mμ	Qian, F. et al., "Expression of the Integrin α4β1 on Melanoma Cells Can Inhibit the Invasive Stage of Metastasis Formation," CELL 77: 335-347 (1994).

EXAMINER Maker Haddad

DATE CONSIDERED

10/27/04

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY, DOCKET NO. A061CIP2	SERIAL NO. 10/086,217
	ORMATION DISCLOSURE OTPE	APPLICANT Gregory R. Mundy and Toshiyuki Yoneda	CONFIRMATION NO. 5114
	( JUN 2 1 2022 \$ )	FILING DATE February 21, 2002	GROUP 1644

EXAMINER INITIAL	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
M#	Shimizu, N. et al., "Disruption of Cell-Cell Contact with Stromal Cells Using Anti-α4integrin Antibody Enhances Sensitivity of Myeloma Cells to Melphalan in Vitro and in Vivo," <u>Twenty-Third Annual Meeting of the American Society for Bone and Mineral Research, Phoenix, Arizona</u> : Presentation Number SU078 (10/14/2001).
m H	Tinhofer, I. et al., "Expression of functional interleukin-15 receptor and autocrine production of interleukin-15 as mechanisms of tumor propagation in multiple myeloma," BLOOD 95: 610-618 (2000).
mH	Vanderkerken, K. et al., "Organ involvement and phenotypic adhesion profile of 5T2 and 5T33 myeloma cells in the C57BL/Kat.wRij mouse," <u>BRIT J CANCER</u> 76: 451-460 (1997).